Alpha-Amylase Variants and Polynucleotides Encoding Same
First Claim
Patent Images
1. An alpha-amylase variant comprising a substitution at a position corresponding to position 176 of SEQ ID NO:
- 1, in particular the substitution K176L, in combination with an alteration at one or more positions corresponding to any of positions 1, 2, 68, 71, 126, 133, 142, 144, 156, 158, 185, 201, 205, 213, 239, 279, 316, 318, 360, 416, 437 and 450 of SEQ ID NO;
1;
wherein the variant has at least 60% and less than 100% sequence identity to (i) the mature polypeptide of any of SEQ ID NOs;
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or (ii) amino acids 1 to 483 of SEQ ID NO;
1, amino acids 1 to 483 of SEQ ID NO;
2, amino acids 1 to 485 of SEQ ID NO;
3, amino acids 1 to 482 of SEQ ID NO;
4, amino acids 1 to 484 of SEQ ID NO;
5, amino acids 1 to 483 of SEQ ID NO;
6, amino acids 1 to 485 of SEQ ID NO;
7, amino acids 1 to 485 of SEQ ID NO;
8, amino acids 1 to 485 of SEQ ID NO;
9, amino acids 1 to 485 of SEQ ID NO;
10, amino acids 1 to 485 of SEQ ID NO;
11, amino acids 1 to 480 of SEQ ID NO;
12, amino acids 1 to 483 of SEQ ID NO;
13 or amino acids 1 to 481 of SEQ ID NO;
14; and
wherein the variant has alpha-amylase activity.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
-
Citations
16 Claims
-
1. An alpha-amylase variant comprising a substitution at a position corresponding to position 176 of SEQ ID NO:
- 1, in particular the substitution K176L, in combination with an alteration at one or more positions corresponding to any of positions 1, 2, 68, 71, 126, 133, 142, 144, 156, 158, 185, 201, 205, 213, 239, 279, 316, 318, 360, 416, 437 and 450 of SEQ ID NO;
1;
wherein the variant has at least 60% and less than 100% sequence identity to (i) the mature polypeptide of any of SEQ ID NOs;
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, or (ii) amino acids 1 to 483 of SEQ ID NO;
1, amino acids 1 to 483 of SEQ ID NO;
2, amino acids 1 to 485 of SEQ ID NO;
3, amino acids 1 to 482 of SEQ ID NO;
4, amino acids 1 to 484 of SEQ ID NO;
5, amino acids 1 to 483 of SEQ ID NO;
6, amino acids 1 to 485 of SEQ ID NO;
7, amino acids 1 to 485 of SEQ ID NO;
8, amino acids 1 to 485 of SEQ ID NO;
9, amino acids 1 to 485 of SEQ ID NO;
10, amino acids 1 to 485 of SEQ ID NO;
11, amino acids 1 to 480 of SEQ ID NO;
12, amino acids 1 to 483 of SEQ ID NO;
13 or amino acids 1 to 481 of SEQ ID NO;
14; and
wherein the variant has alpha-amylase activity. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15)
- 1, in particular the substitution K176L, in combination with an alteration at one or more positions corresponding to any of positions 1, 2, 68, 71, 126, 133, 142, 144, 156, 158, 185, 201, 205, 213, 239, 279, 316, 318, 360, 416, 437 and 450 of SEQ ID NO;
-
10. (canceled)
-
16. (canceled)
Specification